Clinical trial
Study of BAY43-9006 in Patients With Unresectable and/or Metastatic Renal Cell…
NCT00073307 · Bayer, Industry · Completed
Key facts
| NCT number | NCT00073307 |
|---|---|
| Title | Study of BAY43-9006 in Patients With Unresectable and/or Metastatic Renal Cell Cancer |
| Official title | A Phase III Randomized Study of BAY43-9006 in Patients With Unresectable and/or Metastatic Renal Cell Cancer. |
| Lead sponsor | Bayer, Industry |
| Collaborators | Amgen Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Carcinoma, Renal Cell |
| Intervention type | Drug |
| Interventions | Sorafenib (Nexavar, BAY43-9006), Placebo |
| Enrollment | 903 |
| Start date | Nov 1, 2003 |
| Primary completion | Sep 1, 2006 |
| Completion | Apr 1, 2010 |
| First posted | Nov 21, 2003 |
| Last update posted | Feb 6, 2014 |
| Countries | Argentina, Australia, Belgium, Brazil, Canada, Chile, France, Germany, Hungary, Israel, Italy, Netherlands and 7 more |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: